Skip to main content
Signal8

EoCene Ltd. (EOCN)

Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Sector: Pharmaceutical Preparations

Industry: Medical - Pharmaceuticals

Eocene Ltd. logo

Eocene Ltd.

NASDAQ:EOCNHealthcare
AH+0.00%$2.46
Close$2.46-2.77%
Mkt Cap$2.63M
EV-
Float1.03M
O/S1.07M
VOL10K sh
$ Vol$24K
RVOL1.34×
Inst Own1.4%
SI0.8%
Net Cash/Sh-
Dilution
Eocene Ltd. logoNASDAQ:EOCNAH$2.46+0.00%

EoCene Ltd. (EOCN) dilution facts from SEC filings

Snapshot as of Dec 31, 2025, built from 47 SEC filings.

Shelf registration
F-3 filed Nov 14, 2024, effective Nov 21, 2024
Source: POS AM filed Sep 2, 2026
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
1 warrant series recorded as outstanding
Most recent offering
Not measured

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro